Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 296

1.

Correction to: A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.

Penney ME, Parfrey PS, Savas S, Yilmaz YE.

BMC Cancer. 2019 May 10;19(1):437. doi: 10.1186/s12885-019-5672-7.

2.

Meta-analysis of 16 studies of the association of alcohol with colorectal cancer.

McNabb S, Harrison TA, Albanes D, Berndt SI, Brenner H, Caan BJ, Campbell PT, Cao Y, Chang-Claude J, Chan A, Chen Z, English DR, Giles GG, Giovannucci EL, Goodman PJ, Hayes RB, Hoffmeister M, Jacobs EJ, Joshi AD, Larsson SC, Le Marchand L, Li L, Lin Y, Männistö S, Milne RL, Nan H, Newton CC, Ogino S, Parfrey PS, Petersen PS, Potter JD, Schoen RE, Slattery ML, Su YR, Tangen CM, Tucker TC, Weinstein SJ, White E, Wolk A, Woods MO, Phipps AI, Peters U.

Int J Cancer. 2019 Apr 29. doi: 10.1002/ijc.32377. [Epub ahead of print]

PMID:
31037736
3.

A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.

Penney ME, Parfrey PS, Savas S, Yilmaz YE.

BMC Cancer. 2019 Feb 9;19(1):133. doi: 10.1186/s12885-019-5346-5. Erratum in: BMC Cancer. 2019 May 10;19(1):437.

4.

Discovery of common and rare genetic risk variants for colorectal cancer.

Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, Conti DV, Qu C, Jeon J, Edlund CK, Greenside P, Wainberg M, Schumacher FR, Smith JD, Levine DM, Nelson SC, Sinnott-Armstrong NA, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Bamia C, Banbury BL, Baron JA, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Chirlaque MD, Cho SH, Connolly CM, Cross AJ, Cuk K, Curtis KR, de la Chapelle A, Doheny KF, Duggan D, Easton DF, Elias SG, Elliott F, English DR, Feskens EJM, Figueiredo JC, Fischer R, FitzGerald LM, Forman D, Gala M, Gallinger S, Gauderman WJ, Giles GG, Gillanders E, Gong J, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hampel H, Harlid S, Hayes RB, Hofer P, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Hunter DJ, Ibañez-Sanz G, Idos GE, Ingersoll R, Jackson RD, Jacobs EJ, Jenkins MA, Joshi AD, Joshu CE, Keku TO, Key TJ, Kim HR, Kobayashi E, Kolonel LN, Kooperberg C, Kühn T, Küry S, Kweon SS, Larsson SC, Laurie CA, Le Marchand L, Leal SM, Lee SC, Lejbkowicz F, Lemire M, Li CI, Li L, Lieb W, Lin Y, Lindblom A, Lindor NM, Ling H, Louie TL, Männistö S, Markowitz SD, Martín V, Masala G, McNeil CE, Melas M, Milne RL, Moreno L, Murphy N, Myte R, Naccarati A, Newcomb PA, Offit K, Ogino S, Onland-Moret NC, Pardini B, Parfrey PS, Pearlman R, Perduca V, Pharoah PDP, Pinchev M, Platz EA, Prentice RL, Pugh E, Raskin L, Rennert G, Rennert HS, Riboli E, Rodríguez-Barranco M, Romm J, Sakoda LC, Schafmayer C, Schoen RE, Seminara D, Shah M, Shelford T, Shin MH, Shulman K, Sieri S, Slattery ML, Southey MC, Stadler ZK, Stegmaier C, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Thomas SS, Toland AE, Trichopoulou A, Ulrich CM, Van Den Berg DJ, van Duijnhoven FJB, Van Guelpen B, van Kranen H, Vijai J, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Win AK, Wolf CR, Wolk A, Woods MO, Wu AH, Zaidi SH, Zanke BW, Zhang Q, Zheng W, Scacheri PC, Potter JD, Bassik MC, Kundaje A, Casey G, Moreno V, Abecasis GR, Nickerson DA, Gruber SB, Hsu L, Peters U.

Nat Genet. 2019 Jan;51(1):76-87. doi: 10.1038/s41588-018-0286-6. Epub 2018 Dec 3.

5.

Impact of colonoscopic screening in Familial Colorectal Cancer Type X.

Hatfield E, Green JS, Woods MO, Warden G, Parfrey PS.

Mol Genet Genomic Med. 2018 Nov;6(6):1021-1030. doi: 10.1002/mgg3.478. Epub 2018 Oct 9.

6.

Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.

Parfrey PS.

Kidney Int. 2018 Oct;94(4):661-662. doi: 10.1016/j.kint.2018.06.022.

PMID:
30243312
7.

Associations of single nucleotide polymorphisms with mucinous colorectal cancer: genome-wide common variant and gene-based rare variant analyses.

Penney ME, Parfrey PS, Savas S, Yilmaz YE.

Biomark Res. 2018 Jun 13;6:17. doi: 10.1186/s40364-018-0133-z. eCollection 2018.

8.

Hypothesis and data-driven dietary patterns and colorectal Cancer survival: findings from Newfoundland and Labrador colorectal Cancer cohort.

Sharma I, Roebothan B, Zhu Y, Woodrow J, Parfrey PS, Mclaughlin JR, Wang PP.

Nutr J. 2018 May 25;17(1):55. doi: 10.1186/s12937-018-0362-x.

9.

Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake.

Zhu Y, Wang PP, Zhai G, Bapat B, Savas S, Woodrow JR, Campbell PT, Li Y, Yang N, Zhou X, Dicks E, Mclaughlin JR, Parfrey PS.

BMC Cancer. 2018 Feb 6;18(1):155. doi: 10.1186/s12885-018-4026-1.

10.

XRCC3 Thr241Met and TYMS variable number tandem repeat polymorphisms are associated with time-to-metastasis in colorectal cancer.

He Y, Penney ME, Negandhi AA, Parfrey PS, Savas S, Yilmaz YE.

PLoS One. 2018 Feb 2;13(2):e0192316. doi: 10.1371/journal.pone.0192316. eCollection 2018.

11.

Inflammatory diet and risk for colorectal cancer: A population-based case-control study in Newfoundland, Canada.

Sharma I, Zhu Y, Woodrow JR, Mulay S, Parfrey PS, Mclaughlin JR, Hebert JR, Shivappa N, Li Y, Zhou X, Wang PP.

Nutrition. 2017 Oct;42:69-74. doi: 10.1016/j.nut.2017.05.010. Epub 2017 Jun 1.

PMID:
28870481
12.

Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population.

Zhu Y, Wang PP, Zhai G, Bapat B, Savas S, Woodrow JR, Sharma I, Li Y, Zhou X, Yang N, Campbell PT, Dicks E, Parfrey PS, Mclaughlin JR.

Br J Cancer. 2017 Sep 5;117(6):898-906. doi: 10.1038/bjc.2017.242. Epub 2017 Aug 1.

13.

Evaluation of a population-based approach to familial colorectal cancer.

Parfrey PS, Dicks E, Parfrey O, McNicholas PJ, Noseworthy H, Woods MO, Negriin C, Green J.

Clin Genet. 2017 May;91(5):672-682. doi: 10.1111/cge.12877. Epub 2017 Mar 8.

14.

The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.

Abdalla S, Montez-Rath ME, Parfrey PS, Chertow GM.

Contemp Clin Trials. 2016 May;48:119-24. doi: 10.1016/j.cct.2016.04.001. Epub 2016 Apr 11.

PMID:
27080930
15.

Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.

Briggs AH, Parfrey PS, Khan N, Tseng S, Dehmel B, Kubo Y, Chertow GM, Belozeroff V.

Med Decis Making. 2016 Nov;36(8):965-72. doi: 10.1177/0272989X16638312. Epub 2016 Mar 17.

PMID:
26987347
16.

Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.

Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.

Circ Arrhythm Electrophysiol. 2016 Mar;9(3). pii: e003589. doi: 10.1161/CIRCEP.115.003589.

PMID:
26966288
17.

Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients.

Savio AJ, Daftary D, Dicks E, Buchanan DD, Parfrey PS, Young JP, Weisenberger D, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B.

BMC Cancer. 2016 Feb 17;16:113. doi: 10.1186/s12885-016-2149-9.

18.

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

Belozeroff V, Chertow GM, Graham CN, Dehmel B, Parfrey PS, Briggs AH.

Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007. Epub 2015 Oct 9.

19.

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Parfrey PS, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Chertow GM.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):539-46. doi: 10.2215/CJN.06370615. Epub 2015 Nov 27. Review.

20.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

21.

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.

Lewis EF, Claggett B, Parfrey PS, Burdmann EA, McMurray JJ, Solomon SD, Levey AS, Ivanovich P, Eckardt KU, Kewalramani R, Toto R, Pfeffer MA.

Am Heart J. 2015 Aug;170(2):322-9. doi: 10.1016/j.ahj.2015.05.008. Epub 2015 May 22.

PMID:
26299230
22.

Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.

Kubo Y, Sterling LR, Parfrey PS, Gill K, Mahaffey KW, Gioni I, Trotman ML, Dehmel B, Chertow GM.

Pharm Stat. 2015 Jul-Aug;14(4):368. doi: 10.1002/pst.1694. Epub 2015 Jun 10. No abstract available.

PMID:
26096896
23.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
24.

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM.

J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4.

PMID:
26040438
25.

Psychometric properties of the Patient's Perception of Life on Hemodialysis Scale.

Twomey JC, Barrett BJ, Way CY, Churchill DN, Parfrey PS.

J Nurs Meas. 2015;23(1):72-81.

PMID:
25985496
26.

The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS.

Clin J Am Soc Nephrol. 2015 May 7;10(5):800-7. doi: 10.2215/CJN.10221014. Epub 2015 Apr 17.

27.

Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.

Kubo Y, Sterling LR, Parfrey PS, Gill K, Mahaffey KW, Gioni I, Trotman ML, Dehmel B, Chertow GM.

Pharm Stat. 2015 May-Jun;14(3):242-51. doi: 10.1002/pst.1680. Epub 2015 Apr 6. Erratum in: Pharm Stat. 2015 Jul-Aug;14(4):368.

PMID:
25851955
28.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

29.

Clinical genetic research 1: Bias.

Stuckless S, Parfrey PS.

Methods Mol Biol. 2015;1281:333-48. doi: 10.1007/978-1-4939-2428-8_20.

PMID:
25694320
30.

Randomized controlled trials: planning, monitoring, and execution.

Hatfield E, Dicks E, Parfrey PS.

Methods Mol Biol. 2015;1281:273-86. doi: 10.1007/978-1-4939-2428-8_16.

PMID:
25694316
31.

Randomized controlled trials 7: Analysis and interpretation of quality-of-life scores.

Foley RN, Parfrey PS.

Methods Mol Biol. 2015;1281:261-72. doi: 10.1007/978-1-4939-2428-8_15.

PMID:
25694315
32.

Randomized controlled trials 6: On contamination and estimating the actual treatment effect.

Parfrey PS.

Methods Mol Biol. 2015;1281:249-59. doi: 10.1007/978-1-4939-2428-8_14.

PMID:
25694314
33.

Randomized controlled trials 1: Design.

Curtis BM, Barrett BJ, Parfrey PS.

Methods Mol Biol. 2015;1281:159-75. doi: 10.1007/978-1-4939-2428-8_9.

PMID:
25694309
34.

Longitudinal studies 3: Data modeling using standard regression models and extensions.

Ravani P, Barrett BJ, Parfrey PS.

Methods Mol Biol. 2015;1281:93-131. doi: 10.1007/978-1-4939-2428-8_6.

PMID:
25694306
35.

Longitudinal studies 2: Modeling data using multivariate analysis.

Ravani P, Barrett BJ, Parfrey PS.

Methods Mol Biol. 2015;1281:71-92. doi: 10.1007/978-1-4939-2428-8_5.

PMID:
25694305
36.

On framing the research question and choosing the appropriate research design.

Parfrey PS, Ravani P.

Methods Mol Biol. 2015;1281:3-18. doi: 10.1007/978-1-4939-2428-8_1.

PMID:
25694301
37.

Dietary patterns and colorectal cancer: results from a Canadian population-based study.

Chen Z, Wang PP, Woodrow J, Zhu Y, Roebothan B, Mclaughlin JR, Parfrey PS.

Nutr J. 2015 Jan 15;14:8. doi: 10.1186/1475-2891-14-8.

38.

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11.

39.

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators.

J Am Heart Assoc. 2014 Nov 17;3(6):e001363. doi: 10.1161/JAHA.114.001363. Erratum in: J Am Heart Assoc. 2015 Jan;4(1):e000570.

40.

Responsiveness of the patient's perception of hemodialysis scale.

Twomey JC, Parfrey PS, Barrett BJ, Churchill DN, Way CY.

CANNT J. 2014 Apr-Jun;24(2):33-44.

PMID:
25276989
41.

Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype.

Zhu Y, Yang SR, Wang PP, Savas S, Wish T, Zhao J, Green R, Woods M, Sun Z, Roebothan B, Squires J, Buehler S, Dicks E, Zhao J, Mclaughlin JR, Parfrey PS, Campbell PT.

Br J Cancer. 2014 Mar 4;110(5):1359-66. doi: 10.1038/bjc.2014.6. Epub 2014 Jan 21.

42.

Cardiac biomarkers and health-related quality of life in new hemodialysis patients without symptomatic cardiac disease.

Williams CE, Curtis BM, Randell EW, Foley RN, Parfrey PS.

Can J Kidney Health Dis. 2014 Jul 15;1:16. doi: 10.1186/2054-3581-1-16. eCollection 2014.

43.

Dietary N-nitroso compounds and risk of colorectal cancer: a case-control study in Newfoundland and Labrador and Ontario, Canada.

Zhu Y, Wang PP, Zhao J, Green R, Sun Z, Roebothan B, Squires J, Buehler S, Dicks E, Zhao J, Cotterchio M, Campbell PT, Jain M, Parfrey PS, Mclaughlin JR.

Br J Nutr. 2014 Mar 28;111(6):1109-17. doi: 10.1017/S0007114513003462. Epub 2013 Oct 25.

44.

The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.

Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG.

J Clin Endocrinol Metab. 2013 Dec;98(12):4834-44. doi: 10.1210/jc.2013-2975. Epub 2013 Oct 9.

PMID:
24108314
45.

On peginesatide and anemia treatment in CKD.

Parfrey PS, Warden G, Barrett BJ.

Am J Kidney Dis. 2013 Oct;62(4):659-61. doi: 10.1053/j.ajkd.2013.05.008. Epub 2013 Jun 28. No abstract available.

PMID:
23810692
46.

Cinacalcet for cardiovascular disease in patients undergoing dialysis.

Chertow GM, Parfrey PS.

N Engl J Med. 2013 May 9;368(19):1844-5. doi: 10.1056/NEJMc1301247. No abstract available.

PMID:
23656653
47.

Dietary patterns and colorectal cancer recurrence and survival: a cohort study.

Zhu Y, Wu H, Wang PP, Savas S, Woodrow J, Wish T, Jin R, Green R, Woods M, Roebothan B, Buehler S, Dicks E, McLaughlin JR, Campbell PT, Parfrey PS.

BMJ Open. 2013 Feb 7;3(2). pii: e002270. doi: 10.1136/bmjopen-2012-002270. Print 2013.

48.

Development and preliminary testing of the psychosocial adjustment to hereditary diseases scale.

Watkins KE, Way CY, Gregory DM, LeDrew HM, Ludlow VC, Esplen MJ, Dowden JJ, Cox JE, Fitzgerald GW, Parfrey PS.

BMC Psychol. 2013 Apr 30;1(1):7. doi: 10.1186/2050-7283-1-7. eCollection 2013.

49.

Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.

Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.

Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043. Epub 2012 Nov 16.

PMID:
23159232
50.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

Supplemental Content

Loading ...
Support Center